论文部分内容阅读
[目的]评价多西他赛联合奈达铂治疗老年晚期非小细胞肺癌的临床疗效及不良反应。[方法]24例非小细胞肺癌患者采用多西他赛联合奈达铂方案化疗,多西他赛75mg/m2,静脉滴注,d1;奈达铂25mg/m2,静脉滴注d1~3;3周为1个周期,至少治疗2个周期。[结果]24例患者均完成2个以上周期,CR1例,PR10例,有效率(RR)为45.8%。治疗组中位总生存期为11.4个月(95%CI:8.2~13.4个月),主要不良反应为脱发及骨髓抑制,发生率分别为88.71%及85.48%,不良反应大多为I~Ⅱ级。[结论]多西他赛联合奈达铂治疗非小细胞肺癌疗效较好,不良反应较轻。
[Objective] To evaluate the clinical efficacy and adverse reactions of docetaxel combined with nedaplatin in the treatment of elderly patients with advanced non-small cell lung cancer. [Methods] 24 patients with non-small cell lung cancer received docetaxel combined with nedaplatin chemotherapy, docetaxel 75mg / m2, intravenous drip, d1; nedaplatin 25mg / m2, intravenous drip d1 ~ 3; 3 weeks for a period of at least 2 cycles of treatment. [Results] All of the 24 patients completed more than two cycles. The CR1 and PR10 patients had an effective rate (RR) of 45.8%. The median overall survival was 11.4 months (95% CI: 8.2 to 13.4 months) in the treatment group with major adverse effects of alopecia and myelosuppression, rates of 88.71% and 85.48%, respectively, and adverse reactions were mostly grade I to II . [Conclusion] Docetaxel combined with nedaplatin has better curative effect and less adverse reactions in the treatment of non-small cell lung cancer.